Abstract
At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%. Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mancardi GL, Amato MP, D’Alessandro R, Drago F, Milanese C, Popoli P, Provinciali L, Rossi P, Savettieri G, Tedeschi G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Addis A, Martini N (2008) Natalizumab: a country-based pharmacovigilance program. Neurol Sci 29(Suppl 2):S235–S237
Tedeschi G, Amato MP, D’Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Piccinni C, Montanaro N, Periotto L, Iommelli R, Addis A, Martini N, Provinciali L, Mancardi GL (2009) The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci 30(Suppl 2):S163–S165
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910
Conflict of interest
The authors declare that they have no conflict of interest related to the publication of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mancardi, G.L., Tedeschi, G., Amato, M.P. et al. Three years of experience: the Italian registry and safety data update. Neurol Sci 31 (Suppl 3), 295–297 (2011). https://doi.org/10.1007/s10072-010-0356-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-010-0356-8